Sergey Yurasov - 21 Jan 2026 Form 4 Insider Report for Black Diamond Therapeutics, Inc. (BDTX)

Reporting relationship: CHIEF MEDICAL OFFICER
Issuer ticker: BDTX
Reported as of: 21 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jan 2026, 16:05:08 UTC
Prior SEC filing: 31 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Brent Hatzis-Schoch, Attorney-in-Fact

Key filing fact

Sergey Yurasov filed Form 4 for Black Diamond Therapeutics, Inc. (BDTX) on 23 Jan 2026.

Key facts

This page summarizes Sergey Yurasov's Form 4 filing for Black Diamond Therapeutics, Inc. (BDTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 23 Jan 2026, 16:05.

Change

Previous filing in this sequence was filed on 31 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001686295 Primary reporting owner

Yurasov Sergey

Relationship: CHIEF MEDICAL OFFICER
Address: C/O BLACK DIAMOND THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE
Signature: /s/ Brent Hatzis-Schoch, Attorney-in-Fact
Signature date: 23 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BDTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +250,000
Change %
Price: $0.000000
Shares after: 250,000
Date: 21 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 250,000
Exercise price: $2.57
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.